samedan logo
 
 
 
spacer
home > ebr > winter 2003 > cordia-europabio convention 2003
PUBLICATIONS
European Biopharmaceutical Review

CORDIA-EuropaBio Convention 2003

Europe's first true biotechnology convention got off the ground in style in Vienna during the first week of December 2003. Approximately 1,300 delegates from 37 countries attended the Convention, which featured six plenary sessions, 60 conference panel sessions (across health care, industrial and agri-food biotechnology), six workshops, 10 different therapeutic/technology partnering sessions and an international exhibition with a range of companies from across the world.

The conference programme launched directly into the key issues that the European sector faces with the Opening Plenary featuring representation from all stakeholders in the future development of the European biotechnology industry - political, scientific, patient, mainstream industry and SMEs. The EU's Lisbon Summit objective to become the leading knowledge-based economy by 2010 is clearly not realisable on present performance. Even worse, the gap between Europe and North America is widening with Mrs Mary Harney, Deputy Prime Minister of Ireland and incoming President of the EU Competitiveness Council quoting that whilst the US is currently on average "30 per cent richer than Europe", it will be "50 per cent richer by the year 2050" if things continue as they are.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Review by Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Engineered llama antibodies neutralise Covid-19 virus

Researchers have developed a family of engineered nanobodies which neutralise the SARS-CoV-2 virus, targeting the viral spike protein in a novel way.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement